8-K: Pasithea Regains Nasdaq Minimum Bid Price Compliance

Pasithea Therapeutics Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Summary

• Pasithea Therapeutics Corp. (KTTA) received a letter from The Nasdaq Stock Market on December 12, 2025, confirming it has regained compliance with the $1.00 minimum bid price requirement.
• The company's common stock maintained a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days.
• This resolves the non-compliance notice received on June 23, 2025, regarding Nasdaq Listing Rule 5550(a)(2).
• The previous deadline to regain compliance was December 22, 2025.
• Nasdaq has officially closed the matter.

Sentiment

Score: 8

Explanation: The resolution of a significant compliance issue, which could have led to delisting, is a strong positive for the company and its shareholders, removing a major overhang.

Positives

• Regained compliance with Nasdaq's $1.00 minimum bid price requirement, removing the risk of delisting.
• Successfully met the compliance criteria ahead of the December 22, 2025 deadline.
• The matter with Nasdaq is now officially closed.

Negatives

• The company was previously non-compliant with Nasdaq's $1.00 minimum bid price rule, indicating past share price weakness.

Risks

• The risk of delisting from The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement has been resolved.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the resolution of the Nasdaq compliance issue.

Management Comments

• The Company's common stock had maintained a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days to regain compliance with the minimum bid price requirement, and that the matter is now closed.

Industry Context

This announcement is specific to Pasithea Therapeutics' compliance with exchange listing rules and does not directly reflect broader industry trends. Maintaining Nasdaq listing is crucial for public companies to ensure liquidity and investor confidence, a standard expectation across all industries.

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting is removed, preserving liquidity and potentially investor confidence.
• Employees: No direct impact mentioned, but continued listing provides stability.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

While regaining Nasdaq compliance is a significant positive, removing a major delisting risk, this filing does not provide information on the company's underlying operational performance, financial health, or strategic growth initiatives. The previous non-compliance indicates past share price weakness. A 'hold' recommendation is appropriate until further operational and financial updates are available to assess the company's fundamental value and future prospects beyond just listing compliance.

Keywords

Pasithea Therapeutics, KTTA, Nasdaq compliance, minimum bid price, stock market, listing requirements, delisting risk, corporate governance